On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the December 2022 CRG meeting.
Actions in this consultation include:
- Donepezil, galantamine and rivastigmine for mild to moderate Alzheimer’s disease, Lewy body dementia, and Parkinson’s disease: Green (specialist advice)
- Cyclogest added to formulary as an option for vaginal micronised progesterone for prevention of miscarriage
All links to MHRA drug safety updates will be added to formulary as appropriate.
To take part in this consultation, visit the consultations page. The consultation period is open until 5pm on Thursday 26th January 2023.